Topic resource collection
Approved comparison material connected to this topic.
8 resourcesRead both sides
Before stacking any peptides with DSIP, assess receptor pathway overlap, timing requirements, and known interaction data. This table summarises compatibility across common research peptide classes based on mechanism, documented i…
MK 677 Ghrelin receptor agonist (GH/IGF-1) Yes Evening dose, 8+ hours after Cerebrolysin Synergistic. GH elevation enhances BDNF receptor sensitivity without pathway overlap Thymalin Thymus peptide receptors (immune modulation) A…
Survodutide + Semaglutide High (both GLP-1R agonists) GLP-1 receptor saturation, accelerated GI side effects, diminished dose-response curve Avoid simultaneous use; if combining, reduce survodutide dose by 40% and monitor gastric…
GH Secretagogues (CJC-1295, Ipamorelin, GHRP-2) Ghrelin receptor agonism → pituitary GH release None. Operates through independent pathway Dose 4–6 hours apart to separate injection sites High Ideal stack. No shared receptors, co…
Tesofensine + Tirzepatide Non-overlapping (monoamine vs GLP-1 receptor) Low. No shared pathways Tesofensine AM, Tirzepatide weekly Weekly BP/HR for first month Safe stack. Additive fat loss through independent mechanisms Tesofens…
Orforglipron + MK 677 None (GLP-1 vs ghrelin pathways) Low. No gastric motility conflict Growth hormone studies support combination High. Orthogonal mechanisms Orforglipron + Thymalin None (metabolic vs immune) Minimal. No shared…
GLP-1 Agonists (semaglutide, tirzepatide) Satiety signaling, gastric emptying None. Targets GLP-1 receptors vs NNMT enzyme Any timing (long half-life) High Complementary mechanisms. One reduces intake, other increases oxidation G…
Before committing to a multi-peptide protocol, understanding which combinations deliver synergistic benefits versus redundant effects prevents wasted compounds and disappointing results. This table compares how KLOW pairs with co…